sanofi has built up a considerable trade since 2003, and the establishment to go with it, as genrx looked on.
1 this is an application by the cross-claimant sanofi-aventis (sanofi) for an interlocutory injunction restraining infringement of a patent by the cross-respondent genrx pty ltd (genrx) which has made application for revocation of that patent.
7 it is accepted for present purposes that genrx threatens to import and sell clopidogrel bisulphate products which come within claims 1, 3, 10 and 11 of the patent in suit.